Predictors of systemic recurrence and disease‐specific survival after ipsilateral breast tumor recurrence
BACKGROUND In patients with breast carcinoma, ipsilateral breast tumor recurrence (IBTR) after breast‐conserving therapy (BCT) is an independent predictor of systemic recurrence and disease‐specific survival (DSS). However, only a subgroup of patients with IBTR develop systemic recurrences. Therefor...
Saved in:
Published in | Cancer Vol. 104; no. 3; pp. 479 - 490 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.08.2005
Wiley-Liss |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | BACKGROUND
In patients with breast carcinoma, ipsilateral breast tumor recurrence (IBTR) after breast‐conserving therapy (BCT) is an independent predictor of systemic recurrence and disease‐specific survival (DSS). However, only a subgroup of patients with IBTR develop systemic recurrences. Therefore, the management of isolated IBTR remains controversial. The objective of the current study was to identify determinants of systemic recurrence and DSS after IBTR.
METHODS
The medical records of 120 women who underwent BCT for Stage 0–III breast carcinoma between 1971 and 1996 and who subsequently developed isolated IBTR were reviewed. Clinicopathologic factors were studied using univariate and multivariate analyses for their association with DSS and the development of systemic recurrence after IBTR.
RESULTS
The median time to IBTR was 59 months. At a median follow‐up of 80 months after IBTR, 45 patients (37.5%) had a systemic recurrence. Initial lymph node status was the strongest predictor of systemic recurrence according to the a univariate analysis (P = 0.001). Other significant factors included lymphovascular invasion (LVI) in the primary tumor, time to IBTR ≤ 48 months, clinical and pathologic IBTR tumor size > 1 cm, LVI in the recurrent tumor, and skin involvement at IBTR. In a multivariate logistic regression analysis, initially positive lymph node status (relative risk [RR], 5.3; 95% confidence interval [95% CI], 1.4–20.1; P = 0.015) and skin involvement at IBTR (RR, 15.1; 95% CI, 1.5–153.8; P = 0.022) remained independent predictors of systemic recurrence. The 5‐year and 10‐year DSS rates after IBTR were 78% and 68%, respectively. In a multivariate Cox proportional hazards model analysis, only LVI in the recurrent tumor was found to be an independent predictor of DSS (RR, 4.6; 95% CI, 1.5–14.1; P = 0.008).
CONCLUSIONS
Patients who initially had lymph node‐positive disease or skin involvement or LVI at IBTR represented especially high‐risk groups that warranted consideration for aggressive, systemic treatment and novel, targeted therapies after IBTR. Determinants of prognosis after IBTR should be taken into account when evaluating the need for further systemic therapy and designing risk‐stratified clinical trials. Cancer 2005. © 2005 American Cancer Society.
The management of patients with ipsilateral breast tumor recurrences (IBTR) remains controversial. In this study, the authors found that initial lymph node‐positive disease and skin involvement or lymphovascular invasion at IBTR were independent predictors of poor outcome after IBTR. |
---|---|
AbstractList | Abstract
BACKGROUND
In patients with breast carcinoma, ipsilateral breast tumor recurrence (IBTR) after breast‐conserving therapy (BCT) is an independent predictor of systemic recurrence and disease‐specific survival (DSS). However, only a subgroup of patients with IBTR develop systemic recurrences. Therefore, the management of isolated IBTR remains controversial. The objective of the current study was to identify determinants of systemic recurrence and DSS after IBTR.
METHODS
The medical records of 120 women who underwent BCT for Stage 0–III breast carcinoma between 1971 and 1996 and who subsequently developed isolated IBTR were reviewed. Clinicopathologic factors were studied using univariate and multivariate analyses for their association with DSS and the development of systemic recurrence after IBTR.
RESULTS
The median time to IBTR was 59 months. At a median follow‐up of 80 months after IBTR, 45 patients (37.5%) had a systemic recurrence. Initial lymph node status was the strongest predictor of systemic recurrence according to the a univariate analysis (
P
= 0.001). Other significant factors included lymphovascular invasion (LVI) in the primary tumor, time to IBTR ≤ 48 months, clinical and pathologic IBTR tumor size > 1 cm, LVI in the recurrent tumor, and skin involvement at IBTR. In a multivariate logistic regression analysis, initially positive lymph node status (relative risk [RR], 5.3; 95% confidence interval [95% CI], 1.4–20.1;
P
= 0.015) and skin involvement at IBTR (RR, 15.1; 95% CI, 1.5–153.8;
P
= 0.022) remained independent predictors of systemic recurrence. The 5‐year and 10‐year DSS rates after IBTR were 78% and 68%, respectively. In a multivariate Cox proportional hazards model analysis, only LVI in the recurrent tumor was found to be an independent predictor of DSS (RR, 4.6; 95% CI, 1.5–14.1;
P
= 0.008).
CONCLUSIONS
Patients who initially had lymph node‐positive disease or skin involvement or LVI at IBTR represented especially high‐risk groups that warranted consideration for aggressive, systemic treatment and novel, targeted therapies after IBTR. Determinants of prognosis after IBTR should be taken into account when evaluating the need for further systemic therapy and designing risk‐stratified clinical trials. Cancer 2005. © 2005 American Cancer Society.
The management of patients with ipsilateral breast tumor recurrences (IBTR) remains controversial. In this study, the authors found that initial lymph node‐positive disease and skin involvement or lymphovascular invasion at IBTR were independent predictors of poor outcome after IBTR. BACKGROUNDIn patients with breast carcinoma, ipsilateral breast tumor recurrence (IBTR) after breast-conserving therapy (BCT) is an independent predictor of systemic recurrence and disease-specific survival (DSS). However, only a subgroup of patients with IBTR develop systemic recurrences. Therefore, the management of isolated IBTR remains controversial. The objective of the current study was to identify determinants of systemic recurrence and DSS after IBTR.METHODSThe medical records of 120 women who underwent BCT for Stage 0-III breast carcinoma between 1971 and 1996 and who subsequently developed isolated IBTR were reviewed. Clinicopathologic factors were studied using univariate and multivariate analyses for their association with DSS and the development of systemic recurrence after IBTR.RESULTSThe median time to IBTR was 59 months. At a median follow-up of 80 months after IBTR, 45 patients (37.5%) had a systemic recurrence. Initial lymph node status was the strongest predictor of systemic recurrence according to the a univariate analysis (P = 0.001). Other significant factors included lymphovascular invasion (LVI) in the primary tumor, time to IBTR < or = 48 months, clinical and pathologic IBTR tumor size > 1 cm, LVI in the recurrent tumor, and skin involvement at IBTR. In a multivariate logistic regression analysis, initially positive lymph node status (relative risk [RR], 5.3; 95% confidence interval [95% CI], 1.4-20.1; P = 0.015) and skin involvement at IBTR (RR, 15.1; 95% CI, 1.5-153.8; P = 0.022) remained independent predictors of systemic recurrence. The 5-year and 10-year DSS rates after IBTR were 78% and 68%, respectively. In a multivariate Cox proportional hazards model analysis, only LVI in the recurrent tumor was found to be an independent predictor of DSS (RR, 4.6; 95% CI, 1.5-14.1; P = 0.008).CONCLUSIONSPatients who initially had lymph node-positive disease or skin involvement or LVI at IBTR represented especially high-risk groups that warranted consideration for aggressive, systemic treatment and novel, targeted therapies after IBTR. Determinants of prognosis after IBTR should be taken into account when evaluating the need for further systemic therapy and designing risk-stratified clinical trials. In patients with breast carcinoma, ipsilateral breast tumor recurrence (IBTR) after breast-conserving therapy (BCT) is an independent predictor of systemic recurrence and disease-specific survival (DSS). However, only a subgroup of patients with IBTR develop systemic recurrences. Therefore, the management of isolated IBTR remains controversial. The objective of the current study was to identify determinants of systemic recurrence and DSS after IBTR. The medical records of 120 women who underwent BCT for Stage 0-III breast carcinoma between 1971 and 1996 and who subsequently developed isolated IBTR were reviewed. Clinicopathologic factors were studied using univariate and multivariate analyses for their association with DSS and the development of systemic recurrence after IBTR. The median time to IBTR was 59 months. At a median follow-up of 80 months after IBTR, 45 patients (37.5%) had a systemic recurrence. Initial lymph node status was the strongest predictor of systemic recurrence according to the a univariate analysis (P = 0.001). Other significant factors included lymphovascular invasion (LVI) in the primary tumor, time to IBTR < or = 48 months, clinical and pathologic IBTR tumor size > 1 cm, LVI in the recurrent tumor, and skin involvement at IBTR. In a multivariate logistic regression analysis, initially positive lymph node status (relative risk [RR], 5.3; 95% confidence interval [95% CI], 1.4-20.1; P = 0.015) and skin involvement at IBTR (RR, 15.1; 95% CI, 1.5-153.8; P = 0.022) remained independent predictors of systemic recurrence. The 5-year and 10-year DSS rates after IBTR were 78% and 68%, respectively. In a multivariate Cox proportional hazards model analysis, only LVI in the recurrent tumor was found to be an independent predictor of DSS (RR, 4.6; 95% CI, 1.5-14.1; P = 0.008). Patients who initially had lymph node-positive disease or skin involvement or LVI at IBTR represented especially high-risk groups that warranted consideration for aggressive, systemic treatment and novel, targeted therapies after IBTR. Determinants of prognosis after IBTR should be taken into account when evaluating the need for further systemic therapy and designing risk-stratified clinical trials. BACKGROUND In patients with breast carcinoma, ipsilateral breast tumor recurrence (IBTR) after breast‐conserving therapy (BCT) is an independent predictor of systemic recurrence and disease‐specific survival (DSS). However, only a subgroup of patients with IBTR develop systemic recurrences. Therefore, the management of isolated IBTR remains controversial. The objective of the current study was to identify determinants of systemic recurrence and DSS after IBTR. METHODS The medical records of 120 women who underwent BCT for Stage 0–III breast carcinoma between 1971 and 1996 and who subsequently developed isolated IBTR were reviewed. Clinicopathologic factors were studied using univariate and multivariate analyses for their association with DSS and the development of systemic recurrence after IBTR. RESULTS The median time to IBTR was 59 months. At a median follow‐up of 80 months after IBTR, 45 patients (37.5%) had a systemic recurrence. Initial lymph node status was the strongest predictor of systemic recurrence according to the a univariate analysis (P = 0.001). Other significant factors included lymphovascular invasion (LVI) in the primary tumor, time to IBTR ≤ 48 months, clinical and pathologic IBTR tumor size > 1 cm, LVI in the recurrent tumor, and skin involvement at IBTR. In a multivariate logistic regression analysis, initially positive lymph node status (relative risk [RR], 5.3; 95% confidence interval [95% CI], 1.4–20.1; P = 0.015) and skin involvement at IBTR (RR, 15.1; 95% CI, 1.5–153.8; P = 0.022) remained independent predictors of systemic recurrence. The 5‐year and 10‐year DSS rates after IBTR were 78% and 68%, respectively. In a multivariate Cox proportional hazards model analysis, only LVI in the recurrent tumor was found to be an independent predictor of DSS (RR, 4.6; 95% CI, 1.5–14.1; P = 0.008). CONCLUSIONS Patients who initially had lymph node‐positive disease or skin involvement or LVI at IBTR represented especially high‐risk groups that warranted consideration for aggressive, systemic treatment and novel, targeted therapies after IBTR. Determinants of prognosis after IBTR should be taken into account when evaluating the need for further systemic therapy and designing risk‐stratified clinical trials. Cancer 2005. © 2005 American Cancer Society. The management of patients with ipsilateral breast tumor recurrences (IBTR) remains controversial. In this study, the authors found that initial lymph node‐positive disease and skin involvement or lymphovascular invasion at IBTR were independent predictors of poor outcome after IBTR. |
Author | Hunt, Kelly K. Singletary, S. Eva Mirza, Nadeem Q. Ames, Frederick C. Meric‐Bernstam, Funda Bedrosian, Isabelle Ross, Merrick I. Kuerer, Henry M. Babiera, Gildy V. Shen, Jeannie Feig, Barry W. Buchholz, Thomas A. Cristofanilli, Massimo |
Author_xml | – sequence: 1 givenname: Jeannie surname: Shen fullname: Shen, Jeannie – sequence: 2 givenname: Kelly K. surname: Hunt fullname: Hunt, Kelly K. – sequence: 3 givenname: Nadeem Q. surname: Mirza fullname: Mirza, Nadeem Q. – sequence: 4 givenname: Thomas A. surname: Buchholz fullname: Buchholz, Thomas A. – sequence: 5 givenname: Gildy V. surname: Babiera fullname: Babiera, Gildy V. – sequence: 6 givenname: Henry M. surname: Kuerer fullname: Kuerer, Henry M. – sequence: 7 givenname: Isabelle surname: Bedrosian fullname: Bedrosian, Isabelle – sequence: 8 givenname: Merrick I. surname: Ross fullname: Ross, Merrick I. – sequence: 9 givenname: Frederick C. surname: Ames fullname: Ames, Frederick C. – sequence: 10 givenname: Barry W. surname: Feig fullname: Feig, Barry W. – sequence: 11 givenname: S. Eva surname: Singletary fullname: Singletary, S. Eva – sequence: 12 givenname: Massimo surname: Cristofanilli fullname: Cristofanilli, Massimo – sequence: 13 givenname: Funda surname: Meric‐Bernstam fullname: Meric‐Bernstam, Funda email: fmeric@mdanderson.org |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16964605$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/15968686$$D View this record in MEDLINE/PubMed |
BookMark | eNp90M1KHTEUB_BQlHq1bvoAMhu7EEaTTJI7WZaL1YKolBbcDecmJ5A6H7c5M5a78xF8Rp_E2HvBriSLfP34H_jvs51-6JGxz4KfCs7lmetdOpVCSvWBzQS385ILJXfYjHNel1pVd3tsn-h3vs6lrj6yPaGtqfOasfvbhD66cUhUDKGgNY3YRVckdFNK2DssoPeFj4RA-Pz4RCt0MWRBU3qID9AWEEZMRVxRbCGf8ssyZTwW49QN6b-kT2w3QEt4uN0P2K9v5z8Xl-XVzcX3xder0lW2UqX11lgX9FIhqOCdljrA3HionbReGiO0V9yjr-oAUHkfDFQifyqxRKtldcC-bHJXafgzIY1NF8lh20KPw0SNqXMPta4zPNlAlwaihKFZpdhBWjeCN6_VNq_VNv-qzfhomzotO_RvdNtlBsdbAOSgDQl6F-nNGWuU4To7sXF_Y4vrd0Y2i-vFj83wF3phlu4 |
CODEN | CANCAR |
CitedBy_id | crossref_primary_10_1097_GRF_0000000000000243 crossref_primary_10_4048_jbc_2011_14_2_124 crossref_primary_10_1111_j_1524_4741_2009_00716_x crossref_primary_10_1155_2012_937658 crossref_primary_10_1155_2014_639534 crossref_primary_10_1007_s12609_023_00498_y crossref_primary_10_1007_s00066_009_1983_y crossref_primary_10_1016_j_radonc_2011_12_019 crossref_primary_10_1016_j_crad_2009_05_006 crossref_primary_10_1016_j_femme_2022_01_001 crossref_primary_10_1016_j_jgyn_2007_11_027 crossref_primary_10_1016_j_critrevonc_2013_08_014 crossref_primary_10_1053_j_sembd_2007_11_002 crossref_primary_10_1186_s12957_016_0881_x crossref_primary_10_1245_s10434_008_0153_2 crossref_primary_10_1177_10732748221089412 crossref_primary_10_1016_j_jbi_2016_01_017 crossref_primary_10_1093_annonc_mdm185 crossref_primary_10_1002_cncr_25767 crossref_primary_10_1016_j_amjsurg_2009_07_009 crossref_primary_10_1186_1471_2407_10_479 crossref_primary_10_1111_j_1365_2702_2009_03145_x crossref_primary_10_1002_jso_23642 crossref_primary_10_1016_j_medcli_2009_05_020 crossref_primary_10_1016_j_medcli_2009_03_036 crossref_primary_10_1016_j_radonc_2011_03_011 crossref_primary_10_1016_j_clbc_2017_03_008 crossref_primary_10_1016_j_radi_2008_08_005 crossref_primary_10_1016_j_breast_2007_11_004 crossref_primary_10_1007_s10549_010_0862_7 crossref_primary_10_3816_CBC_2008_n_014 |
Cites_doi | 10.1002/cncr.11143 10.1002/cncr.11222 10.1200/JCO.2002.02.026 10.1016/0959-8049(94)00526-B 10.1200/JCO.1995.13.12.2869 10.1200/JCO.1998.16.2.480 10.1056/NEJM199710023371402 10.1016/S0039-6109(03)00034-3 10.1200/JCO.2001.19.18.3828 10.1200/JCO.1996.14.1.52 10.1080/028418699432716 10.1093/jnci/87.1.19 10.1007/BF01807163 10.1002/1097-0142(20010415)91:8 <1679::AID-CNCR1183>3.0.CO;2-8 10.1016/S0360-3016(98)00424-6 10.1200/JCO.1999.17.1.101 10.1093/jnci/92.14.1143 10.1200/JCO.2000.18.8.1696 10.1016/S0360-3016(01)01625-X 10.1056/NEJMoa022152 10.1056/NEJM199710023371401 10.1016/j.ijrobp.2004.06.011 10.1200/JCO.2001.19.6.1688 10.1056/NEJMoa020989 10.1002/cncr.20257 10.1002/1097-0142(19930401)71:7<2395::AID-CNCR2820710735>3.0.CO;2-C 10.1200/JCO.1994.12.10.2071 10.1016/S0360-3016(97)00917-6 10.1016/S0140-6736(96)02133-2 10.1002/(SICI)1097-0142(19990115)85:2<437::AID-CNCR23>3.0.CO;2-1 10.1016/S0360-3016(00)01378-X 10.1200/JCO.1993.11.1.44 10.1016/0140-6736(91)90475-5 10.1002/cncr.10952 10.1148/radiology.188.1.8511295 10.1016/S1470-2045(02)00683-6 10.1093/jnci/djh013 10.1016/0360-3016(94)90513-4 |
ContentType | Journal Article |
Copyright | Copyright © 2005 American Cancer Society 2005 INIST-CNRS (c) 2005 American Cancer Society. |
Copyright_xml | – notice: Copyright © 2005 American Cancer Society – notice: 2005 INIST-CNRS – notice: (c) 2005 American Cancer Society. |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1002/cncr.21224 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1097-0142 |
EndPage | 490 |
ExternalDocumentID | 10_1002_cncr_21224 15968686 16964605 CNCR21224 |
Genre | article Research Support, U.S. Gov't, P.H.S Comparative Study Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: National Institutes of Health |
GroupedDBID | --- -~X .3N .GA .Y3 05W 0R~ 10A 1CY 1L6 1OC 24P 29B 31~ 33P 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AARRQ AAWTL AAXRX AAZKR ABCQN ABCUV ABEML ABHFT ABIJN ABIVO ABJNI ABLJU ABOCM ABPPZ ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AGNAY AHBTC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C1A C45 CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EJD EX3 F00 F01 F04 F5P FD6 FUBAC G-S G.N GNP GODZA GX1 H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M J5H JPC KBYEO KQQ KZ1 L7B LATKE LAW LC2 LC3 LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NEJ NF~ NNB O66 O9- OHT OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 QRW R.K ROL RWI RX1 SJN SUPJJ TEORI UDS UHB V2E V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WJL WOHZO WQJ WRC WVDHM WXI WXSBR XG1 XPP XV2 Z0Y ZGI ZZTAW ~IA ~WT .GJ 08R AAJUZ AAUGY AAVGM ABCVL ABHUG ABPTK ABWRO ACXME ADAWD ADDAD AFVGU AGJLS AI. AKALU EMOBN HF~ H~9 IQODW LMP RSU RYL VH1 WHG XFK Y6R YQJ ZA5 ZXP CGR CUY CVF ECM EIF NPM AAQOH AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c3934-9d969cf5b4ea4fdc525fa76da8c29d26615d40ded38faa3ddf6a318c241be9523 |
IEDL.DBID | DR2 |
ISSN | 0008-543X |
IngestDate | Fri Aug 16 21:50:07 EDT 2024 Fri Aug 23 02:13:01 EDT 2024 Sat Sep 28 07:43:21 EDT 2024 Sun Oct 22 16:07:11 EDT 2023 Sat Aug 24 01:02:21 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | predictors Relapse Breast disease Breast tumor systemic recurrence Survival Mammary gland diseases Ipsilateral Cancerology breast carcinoma Systemic disease ipsilateral breast tumor recurrence Predictive factor |
Language | English |
License | CC BY 4.0 (c) 2005 American Cancer Society. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3934-9d969cf5b4ea4fdc525fa76da8c29d26615d40ded38faa3ddf6a318c241be9523 |
Notes | Fax: (713) 745‐4926 Presented in part at the 27th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8–11, 2004. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.21224 |
PMID | 15968686 |
PQID | 68072858 |
PQPubID | 23479 |
PageCount | 12 |
ParticipantIDs | proquest_miscellaneous_68072858 crossref_primary_10_1002_cncr_21224 pubmed_primary_15968686 pascalfrancis_primary_16964605 wiley_primary_10_1002_cncr_21224_CNCR21224 |
PublicationCentury | 2000 |
PublicationDate | 1 August 2005 |
PublicationDateYYYYMMDD | 2005-08-01 |
PublicationDate_xml | – month: 08 year: 2005 text: 1 August 2005 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Hoboken |
PublicationPlace_xml | – name: Hoboken – name: New York, NY – name: United States |
PublicationTitle | Cancer |
PublicationTitleAlternate | Cancer |
PublicationYear | 2005 |
Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley-Liss |
Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley-Liss |
References | 2001; 91 2004; 100 1997; 337 1995; 31A 2000; 48 2002; 95 1995; 13 2000; 92 2002; 3 1999; 43 1999; 85 2005; 61 1991; 338 1996; 14 1998; 40 2003; 97 1996; 348 1993; 188 1998; 16 2004; 96 2000; 18 2004; 18 2002; 20 2000 1993; 71 1999; 17 1993; 11 1999; 38 1995; 87 2001; 19 1994; 12 1996; 41 2002; 347 2003; 83 1994; 30 2001; 51 e_1_2_6_31_2 e_1_2_6_30_2 e_1_2_6_18_2 e_1_2_6_19_2 e_1_2_6_12_2 e_1_2_6_35_2 e_1_2_6_13_2 e_1_2_6_34_2 e_1_2_6_10_2 e_1_2_6_33_2 e_1_2_6_11_2 e_1_2_6_32_2 e_1_2_6_16_2 e_1_2_6_39_2 e_1_2_6_17_2 e_1_2_6_38_2 e_1_2_6_14_2 e_1_2_6_37_2 e_1_2_6_15_2 e_1_2_6_36_2 e_1_2_6_20_2 e_1_2_6_41_2 e_1_2_6_40_2 e_1_2_6_8_2 e_1_2_6_7_2 e_1_2_6_9_2 e_1_2_6_29_2 e_1_2_6_4_2 e_1_2_6_3_2 e_1_2_6_6_2 Lannin DR (e_1_2_6_27_2) 2004; 18 e_1_2_6_5_2 e_1_2_6_24_2 e_1_2_6_23_2 e_1_2_6_2_2 e_1_2_6_22_2 e_1_2_6_21_2 e_1_2_6_28_2 e_1_2_6_26_2 e_1_2_6_25_2 |
References_xml | – volume: 11 start-page: 44 year: 1993 end-page: 48 article-title: Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early‐stage breast cancer publication-title: J Clin Oncol. – volume: 347 start-page: 1227 year: 2002 end-page: 1232 article-title: Twenty‐year follow‐up of a randomized study comparing breast‐conserving surgery with radical mastectomy for early breast cancer publication-title: N Engl J Med. – volume: 71 start-page: 2395 year: 1993 end-page: 2409 article-title: Management of locally recurrent breast cancer publication-title: Cancer. – volume: 20 start-page: 3628 year: 2002 end-page: 3636 article-title: Revision of the American Joint Committee on Cancer staging system for breast cancer publication-title: J Clin Oncol. – volume: 13 start-page: 2869 year: 1995 end-page: 2878 article-title: Adequate locoregional treatment for early breast cancer may prevent secondary dissemination publication-title: J Clin Oncol. – volume: 347 start-page: 1233 year: 2002 end-page: 1241 article-title: Twenty‐year follow‐up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer publication-title: N Engl J Med. – volume: 337 start-page: 949 year: 1997 end-page: 955 article-title: Postoperative radiotherapy in high‐risk premenopausal women with breast cancer who receive adjuvant chemotherapy publication-title: N Engl J Med. – volume: 41 start-page: 177 year: 1996 end-page: 185 article-title: Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy publication-title: Breast Cancer Res Treat. – year: 2000 – volume: 31A start-page: 690 year: 1995 end-page: 698 article-title: Prognostic factors for survival after breast conserving therapy for Stage I and II breast cancer. The role of local recurrence publication-title: Eur J Cancer. – volume: 83 start-page: 803 year: 2003 end-page: 819 article-title: Staging system for breast cancer: revisions for the 6th edition of the AJCC cancer staging manual publication-title: Surg Clin North Am. – volume: 87 start-page: 19 year: 1995 end-page: 27 article-title: Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events publication-title: J Natl Cancer Inst. – volume: 3 start-page: 183 year: 2002 end-page: 187 article-title: Ipsilateral local recurrence of breast cancer: determinant or indicator of poor prognosis? publication-title: Lancet Oncol. – volume: 19 start-page: 1688 year: 2001 end-page: 1697 article-title: Differences in risk factors for local and distant recurrence after breast‐conserving therapy or mastectomy for Stage I and II breast cancer: pooled results of two large European randomized trials publication-title: J Clin Oncol. – volume: 48 start-page: 1281 year: 2000 end-page: 1289 article-title: True recurrence versus new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management publication-title: Int J Radiat Oncol Biol Phys. – volume: 18 start-page: 272 year: 2004 end-page: 279 article-title: End results of salvage therapy after failure of breast‐conservation surgery publication-title: Oncology (Huntingt). – volume: 61 start-page: 348 year: 2005 end-page: 357 article-title: Prognosis after local recurrence after conservative surgery and radiation for early‐stage breast cancer publication-title: Int J Radiat Oncol Biol Phys. – volume: 188 start-page: 189 year: 1993 end-page: 194 article-title: Breast cancer recurrence after lumpectomy and radiation therapy for early‐stage disease: prognostic significance of detection method publication-title: Radiology. – volume: 337 start-page: 956 year: 1997 end-page: 962 article-title: Adjuvant radiotherapy and chemotherapy in node‐positive premenopausal women with breast cancer publication-title: N Engl J Med. – volume: 14 start-page: 52 year: 1996 end-page: 57 article-title: Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse publication-title: J Clin Oncol. – volume: 92 start-page: 1143 year: 2000 end-page: 1150 article-title: Long‐term results of a randomized trial comparing breast‐conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial publication-title: J Natl Cancer Inst. – volume: 91 start-page: 1679 year: 2001 end-page: 1687 article-title: Fifteen‐year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol‐06 publication-title: Cancer. – volume: 348 start-page: 708 year: 1996 end-page: 713 article-title: Randomised controlled trial of conservation therapy for breast cancer: 6‐year analysis of the Scottish trial publication-title: Lancet. – volume: 18 start-page: 1696 year: 2000 end-page: 1708 article-title: Role of isolated locoregional recurrence of breast cancer: results of four prospective studies publication-title: J Clin Oncol. – volume: 16 start-page: 480 year: 1998 end-page: 486 article-title: Skin recurrences after breast‐conserving therapy for early‐stage breast cancer publication-title: J Clin Oncol. – volume: 38 start-page: 9 issue: Suppl 13 year: 1999 end-page: 17 article-title: Ipsilateral breast tumor recurrence following breast‐conserving surgery for early‐stage invasive cancer publication-title: Acta Oncol. – volume: 40 start-page: 859 year: 1998 end-page: 867 article-title: Local recurrence after breast‐conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival publication-title: Int J Radiat Oncol Biol Phys. – volume: 85 start-page: 437 year: 1999 end-page: 446 article-title: Local recurrence after breast conservation therapy for early stage breast carcinoma: detection, treatment, and outcome in 266 patients publication-title: Cancer. – volume: 19 start-page: 3828 year: 2001 end-page: 3835 article-title: Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast‐conserving surgery publication-title: J Clin Oncol. – volume: 97 start-page: 910 year: 2003 end-page: 919 article-title: Does local recurrence affect the rate of distant metastases and survival in patients with early‐stage breast carcinoma treated with breast‐conserving therapy? publication-title: Cancer. – volume: 12 start-page: 2071 year: 1994 end-page: 2077 article-title: First isolated locoregional recurrence following mastectomy for breast cancer: results of a Phase III multicenter study comparing systemic treatment with observation after excision and radiation publication-title: J Clin Oncol. – volume: 17 start-page: 101 year: 1999 end-page: 109 article-title: Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy publication-title: J Clin Oncol. – volume: 96 start-page: 115 year: 2004 end-page: 121 article-title: Breast‐conserving surgery with or without radiotherapy: pooled‐analysis for risks of ipsilateral breast tumor recurrence and mortality publication-title: J Natl Cancer Inst. – volume: 97 start-page: 926 year: 2003 end-page: 933 article-title: Positive surgical margins and ipsilateral breast tumor recurrence predict disease‐specific survival after breast‐conserving therapy publication-title: Cancer. – volume: 100 start-page: 2269 year: 2004 end-page: 2280 article-title: Repeat breast‐conserving surgery for in‐breast local breast carcinoma recurrence: the potential role of partial breast irradiation publication-title: Cancer. – volume: 30 start-page: 11 year: 1994 end-page: 16 article-title: Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: results from a randomized trial publication-title: Int J Radiat Oncol Biol Phys. – volume: 95 start-page: 2059 year: 2002 end-page: 2067 article-title: Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences publication-title: Cancer. – volume: 51 start-page: 74 year: 2001 end-page: 80 article-title: Long‐term results of local recurrence after breast conservation treatment for invasive breast cancer publication-title: Int J Radiat Oncol Biol Phys. – volume: 338 start-page: 327 year: 1991 end-page: 331 article-title: Significance of ipsilateral breast tumour recurrence after lumpectomy publication-title: Lancet. – volume: 43 start-page: 11 year: 1999 end-page: 24 article-title: The link between local recurrence and distant metastases in human breast cancer publication-title: Int J Radiat Oncol Biol Phys. – ident: e_1_2_6_11_2 doi: 10.1002/cncr.11143 – ident: e_1_2_6_12_2 doi: 10.1002/cncr.11222 – ident: e_1_2_6_26_2 doi: 10.1200/JCO.2002.02.026 – ident: e_1_2_6_5_2 doi: 10.1016/0959-8049(94)00526-B – ident: e_1_2_6_37_2 doi: 10.1200/JCO.1995.13.12.2869 – ident: e_1_2_6_30_2 doi: 10.1200/JCO.1998.16.2.480 – ident: e_1_2_6_39_2 doi: 10.1056/NEJM199710023371402 – ident: e_1_2_6_25_2 doi: 10.1016/S0039-6109(03)00034-3 – ident: e_1_2_6_10_2 doi: 10.1200/JCO.2001.19.18.3828 – ident: e_1_2_6_6_2 doi: 10.1200/JCO.1996.14.1.52 – ident: e_1_2_6_17_2 doi: 10.1080/028418699432716 – ident: e_1_2_6_4_2 doi: 10.1093/jnci/87.1.19 – ident: e_1_2_6_20_2 doi: 10.1007/BF01807163 – ident: e_1_2_6_18_2 doi: 10.1002/1097-0142(20010415)91:8 <1679::AID-CNCR1183>3.0.CO;2-8 – ident: e_1_2_6_21_2 doi: 10.1016/S0360-3016(98)00424-6 – ident: e_1_2_6_7_2 doi: 10.1200/JCO.1999.17.1.101 – ident: e_1_2_6_14_2 doi: 10.1093/jnci/92.14.1143 – ident: e_1_2_6_9_2 doi: 10.1200/JCO.2000.18.8.1696 – ident: e_1_2_6_32_2 doi: 10.1016/S0360-3016(01)01625-X – ident: e_1_2_6_15_2 doi: 10.1056/NEJMoa022152 – volume: 18 start-page: 272 year: 2004 ident: e_1_2_6_27_2 article-title: End results of salvage therapy after failure of breast‐conservation surgery publication-title: Oncology (Huntingt). contributor: fullname: Lannin DR – ident: e_1_2_6_38_2 doi: 10.1056/NEJM199710023371401 – ident: e_1_2_6_28_2 doi: 10.1016/j.ijrobp.2004.06.011 – ident: e_1_2_6_33_2 doi: 10.1200/JCO.2001.19.6.1688 – ident: e_1_2_6_40_2 – ident: e_1_2_6_16_2 doi: 10.1056/NEJMoa020989 – ident: e_1_2_6_36_2 doi: 10.1002/cncr.20257 – ident: e_1_2_6_24_2 doi: 10.1002/1097-0142(19930401)71:7<2395::AID-CNCR2820710735>3.0.CO;2-C – ident: e_1_2_6_41_2 doi: 10.1200/JCO.1994.12.10.2071 – ident: e_1_2_6_8_2 doi: 10.1016/S0360-3016(97)00917-6 – ident: e_1_2_6_13_2 doi: 10.1016/S0140-6736(96)02133-2 – ident: e_1_2_6_31_2 doi: 10.1002/(SICI)1097-0142(19990115)85:2<437::AID-CNCR23>3.0.CO;2-1 – ident: e_1_2_6_34_2 doi: 10.1016/S0360-3016(00)01378-X – ident: e_1_2_6_23_2 doi: 10.1200/JCO.1993.11.1.44 – ident: e_1_2_6_2_2 doi: 10.1016/0140-6736(91)90475-5 – ident: e_1_2_6_35_2 doi: 10.1002/cncr.10952 – ident: e_1_2_6_29_2 doi: 10.1148/radiology.188.1.8511295 – ident: e_1_2_6_19_2 doi: 10.1016/S1470-2045(02)00683-6 – ident: e_1_2_6_22_2 doi: 10.1093/jnci/djh013 – ident: e_1_2_6_3_2 doi: 10.1016/0360-3016(94)90513-4 |
SSID | ssj0007253 |
Score | 2.0534155 |
Snippet | BACKGROUND
In patients with breast carcinoma, ipsilateral breast tumor recurrence (IBTR) after breast‐conserving therapy (BCT) is an independent predictor of... In patients with breast carcinoma, ipsilateral breast tumor recurrence (IBTR) after breast-conserving therapy (BCT) is an independent predictor of systemic... Abstract BACKGROUND In patients with breast carcinoma, ipsilateral breast tumor recurrence (IBTR) after breast‐conserving therapy (BCT) is an independent... BACKGROUNDIn patients with breast carcinoma, ipsilateral breast tumor recurrence (IBTR) after breast-conserving therapy (BCT) is an independent predictor of... |
SourceID | proquest crossref pubmed pascalfrancis wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 479 |
SubjectTerms | Adult Aged Aged, 80 and over Biological and medical sciences breast carcinoma Breast Neoplasms - diagnosis Breast Neoplasms - mortality Carcinoma in Situ - diagnosis Carcinoma in Situ - mortality Carcinoma, Ductal, Breast - diagnosis Carcinoma, Ductal, Breast - mortality Carcinoma, Lobular - diagnosis Carcinoma, Lobular - mortality Combined Modality Therapy Disease-Free Survival Female Gynecology. Andrology. Obstetrics Humans ipsilateral breast tumor recurrence Lymph Nodes - pathology Mammary gland diseases Medical sciences Middle Aged Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - mortality Neoplasm Staging predictors survival systemic recurrence Tumors |
Title | Predictors of systemic recurrence and disease‐specific survival after ipsilateral breast tumor recurrence |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.21224 https://www.ncbi.nlm.nih.gov/pubmed/15968686 https://search.proquest.com/docview/68072858 |
Volume | 104 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB5CDqVQ-n64j1TQngrebCxblqCXsjSEQkIJDeylGD1hSepd_Lj01J_Q39hf0hnZG3dLKbT4ooMk25rRzEgz8w3Aa-O1PBKep5bPQ4oa2qdaB5MqW7gcG9w48uienomTi_zDsljuwdttLsyAD3F94UY7I8pr2uDatIcTaKitbTPLyDGEApiQ9MgiOp-wo8pshKCcy7TI-fIamzQ7nIbuaKNbG93iwoShosWfTM5dCzaqoOM78Hn78UPkyeWs78zMfv0N1_F__-4u3B5tU_ZuYKZ7sOfr-3DjdPS-P4DLjw21qT4PWwc2gECvLGvozj5mDTJdOzb6fH58-05pnBSKxNoeJRLyNIslydlq066uNOU-XzFDUfEd6_ov6-aXmR7CxfH7T4uTdCzWgFRWPE-VU0LZUJjc6zw4W2RF0KVwWtpMOTIDkPhz5x2XQWvuXBAa5YlFC8J4hcfhR7Bfr2v_BBgvneOoJ50xRzhbqX1phdJhnjmrZKkSeLUlWrUZMDmqAX05q2jdqrhuCRzs0HPqKpQgb3ACL7cErnBPkaNE137dt5WQyD2ykAk8Hug-jS2UkPgk8CZS7y_vrxZni_PYevovnZ_BzYgOG2MMn8N-1_T-Bdo9nTmI_P0TVBoDkg |
link.rule.ids | 315,786,790,1382,27957,27958,46329,46753 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7aFNpA6Tup-0gE7angzcayZOtYloZtm11KSGBvRk9YknoXPy459Sf0N-aXRCM7cbeUQosvOuiBNTOakWbmG4D3ysr8kFsaazp2sdfQNpbSqVhoZlLfoMqgR3c259Oz9MuCLfrYHMyF6fAhbh_cUDLCeY0Cjg_SBwNqqC51NUrQM3QX7nl5Z-FGdTKgR2VJD0I5zmOW0sUtOmlyMIzd0EcP17L2W-O6mhZ_Mjo3bdighI4ed5VW64BdiLEn56O2USN9-Ruy43__3xN41Jun5GPHT0_hji2fwf1Z74B_DuffKmxjiR6ycqTDgV5qUuGzfUgcJLI0pHf7XP34iZmcGI1E6tYfSp6tSahKTpbrenkhMf35gigMjG9I035fVb_M9ALOjj6dTqZxX6_BE1rQNBZGcKEdU6mVqTOaJczJjBuZ60QYtAQ8_cfGGpo7Kakxjkt_pGhvRCgr_I14B7bKVWlfAqGZMdSrSqPUoZ8tkzbTXEg3TowWeSYieHdDtWLdwXIUHQBzUuC-FWHfItjbIOjQlQuODuEI9m8oXHixQl-JLO2qrQuee_bJWR7Bbkf4YSwTPPdfBB8C-f6yfjGZT05C69W_dN6HB9PT2XFx_Hn-9TVsB7DYEHL4BraaqrVvvRnUqL3A7NeCmQe0 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB6SLYRASdo0DydpImhOBW82li1LkEvYdEkfWUJoYC_B6AlLUu_itS899Sf0N_aXRJK962wphRZfdLBkW99IM9bMfANwIjSnZ0TjUOKeCa2G1iHnRoRMJiq2DSyU8-heD8nVXfxplIxW4HyeC1PzQywO3NzK8Pu1W-BTZU5b0lCZy6IbOcfQKryICY6cTF_etuRRadRwUPZomMR4tCAnjU7bvkvq6OWUz-zMmLqkxZ9szmUT1uugwSbcz9--Dj156Fal6MrvvxE7_u_nvYKNxjhFF7U0vYYVnW_B2nXjfn8DDzeFa7sCPWhiUM0CPZaocIf2Pm0Q8Vyhxunz68dPl8fpYpHQrLJbkhVq5GuSo_F0Nn7kLvn5EQkXFl-isvo2KZ6NtA13gw9f-1dhU63BwsxwHDLFCJMmEbHmsVEyiRLDU6I4lRFTzg6w6PeUVpgazrFShnC7oUhrQgjN7P_wDnTySa73AOFUKWwVpRLizI6Wcp1KwrjpRUoymrIA3s1By6Y1KUdW0y9HmZu3zM9bAEdLeLa3EkacOziA4znAmV1UzlPCcz2pZhmhVnpoQgPYrXFv-yaMUHsF8N6j95fnZ_1h_9a39v_l5mNYu7kcZF8-Dj8fwLpnivXxhofQKYtKv7U2UCmOvKg_AXo1BmM |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predictors+of+systemic+recurrence+and+disease%E2%80%90specific+survival+after+ipsilateral+breast+tumor+recurrence&rft.jtitle=Cancer&rft.au=Shen%2C+Jeannie&rft.au=Hunt%2C+Kelly+K.&rft.au=Mirza%2C+Nadeem+Q.&rft.au=Buchholz%2C+Thomas+A.&rft.date=2005-08-01&rft.pub=Wiley+Subscription+Services%2C+Inc.%2C+A+Wiley+Company&rft.issn=0008-543X&rft.eissn=1097-0142&rft.volume=104&rft.issue=3&rft.spage=479&rft.epage=490&rft_id=info:doi/10.1002%2Fcncr.21224&rft.externalDBID=10.1002%252Fcncr.21224&rft.externalDocID=CNCR21224 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |